Dr Reddy’s Laboratories may also join the fray, having sought extra time to submit a bid for the Advent International portfolio company, the people added, saying its non-binding bid is expected to be filed this week. Due diligence will continue over the next four to six weeks, before the final offers are submitted in July.
The health ministry earlier launched the MVPI with the objective to improve patient safety by monitoring, recording and analysing the root cause of adverse events or risks associated with the use of medical devices including in-vitro diagnostics by healthcare professionals or patients/users and suggesting regulatory bodies for appropriate action.
The drugmaker plans to use its new life sciences Advanced Research Centre in the western city of Darmstadt, which it is spending 300 million euros on, to develop services and digital platforms to help scientists work more effectively.
The government in 2021 announced PLI schemes for 14 sectors such as telecommunication, white goods, textiles, manufacturing of medical devices, automobiles, speciality steel, food products, high-efficiency solar PV modules, advanced chemistry cell battery, drones, and pharma with an outlay of Rs 1.97 lakh crore.
Some of these PE-owned platform companies include Advent International-led Cohance Lifesciences / Suven Pharma, PAG and CX Partners-funded Sekhmet Pharmaventures, and Carlyle-backed Viyash Lifesciences and Sequent Scientific (animal API manufacturer).
Indian pharma industry's heavy dependence on imports for active pharmaceutical ingredients (API), key starting materials (KSM) and basic chemicals has been rather alarming, highlighting the need for a resolution.
In 2012, a parliamentary standing committee of the health ministry had observed in its report that some of the state licensing authorities issued manufacturing licences for a large number of FDCs without prior clearance from the central drug authority, resulting in the availability of several FDCs which were not tested for safety and efficacy.
In a significant boost to healthcare infrastructure in the Northeast, Dr Mandaviya dedicated five new facilities in the Regional Institute of Paramedical and Nursing Science (RIPANS) in Aizawl, Mizoram to the nation today.
Fleming is a backward integrated API manufacturer with global leadership in select muscle relaxant, anti-arthritis, and antihistamine APIs with two regulatory-approved manufacturing units. The company sells to customers in over 65 countries across Latin America, Europe, Asia, and MENA.
In a recent meeting held by the drug controller on global clinical trials, the OPPI sought from the government a notification system through the drug regulatory authority's digital portal-SUGAM. It has asked for linking of the SUGAM Portal at Centre and state levels and, then, making public the non-commercial information in respect of the filed/pending applications and the approvals granted, it said.
India's patent laws are unique, featuring stringent criteria for patentability, particularly for secondary patents. To secure approval, these patents must demonstrate a significant therapeutic improvement. This distinctive approach has effectively deterred evergreening practices by pharmaceutical companies, aligning with India's dedication to public health and affordable blockbuster medicines.
Get updates on your preferred social platform
Follow us for the latest news, insider access to events and more.
